MPC-0920 is an orally available, direct thrombin inhibitor. It is designed to address the clinical needs for rapid and predictable anticoagulant action, an improved therapeutic window, predictable patient response and increased efficacy.
MPC-0920 has been the subject of 27 preclinical studies to date, comprising safety, toxicity, pharmacokinetics and formulation.
“MPC-0920 is an intriguing compound in a vitally important therapeutic area,” said Dr Adrian Hobden, President of Myriad Pharmaceuticals. “We look forward to completing the preclinical data package for submission to the FDA this fiscal year.”
According to the company, the total market for medicines to treat thrombotic disorders in 2003 was $6.5 billion.